AstraZeneca

Open: 62.02 Close: 63.47 Change: 1.44

Are you looking for information about AstraZeneca? We programmed an AI to summarize it for you.

The game is changing. There is a new strategy to evaluate AstraZeneca fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, share, drug, say, earnings, vaccine, strong, and the …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

British drugs group AstraZeneca on Thursday said its net profit almost doubled to $6 billion last year. Strong cancer division helped offset a wipeout for sales of Covid treatments. British drug giant will invest $300 million in a new manufacturing facility in Rockville, Maryland.

Today's News

AstraZeneca shares tumble despite posting strong sales for cancer drug. News failed to cheer investors with the companys stock down 3.76% at the time of writing. British drugs group AstraZeneca on Thursday said its net profit almost doubled to $6 billion last year, with a strong cancer division helping offset a wipeout for sales of Covid treatments. AstraZeneca sees revenue and core earnings per share growing by double-digit percentages in 2024. Pharmaceuticals major said as it reported fourth-quarter core earnings below expectations. AstraZeneca PLC (AZN) on Thursday reported fourth-quarter earnings of $960 million. British drug giant will invest $300 million in a new manufacturing facility in Rockville, Maryland, and create 150 new jobs. Astrazeneca says Catalent deal shows need for in-house capacity. UK drugmaker working with Chinese company to develop pill to tackle obesity and type 2 diabetes pill. Astrazeneca has met the $45 billion-by-2023 goal CEO Pascal Soriot established in 2014 when he was fending off a takeover bid from Pfizer. The FDA just granted priority review to AZ and Daiichis tumor-agnostic application for Enhertu. AstraZeneca shares drop despite strong 2024 outlook - channelchek. astrazeneca shares dropped despite strong 24-year outlook - Channelchek All Results Join Log In Menu Close News for more details. AstraZeneca traces its earliest corporate history to 1913. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine. In 1999 Astra and Zeneca Group merged to form Astra Zeneca. AstraZeneca announced it was spinning off six early-stage experimental drugs into a new biotechnology company, known as Viela Bio, valued at US$250 million. In February 2018, AstraZecas announced it would sell the global commercial rights for its drug to treat acid reflux to German company Cheplapharm. AstraZeneca has its corporate headquarters in Cambridge, United Kingdom. Main R&D centres are in Cambridge (UK), Gaithersburg (Maryland, US), Gothenburg (Sweden) and Warsaw (Poland) In September 2021, the lawsuit was finally settled with Astra Zeneca agreeing to deliver 60 million doses of vaccines to EU member states. AstraZeneca plc 2022 Annual Report (Form 20-F). AstraZenecas COVID-19 vaccine gets the green light in the UK UPDATED: Astra Zeneca to ax 1,600, relocate thousands in global R&D reshuffle Astrazeneca drops interest in Gilead Sciences. AstraZeneca bets up to $6 billion on new Daiichi cancer drug Oxford vaccine researchers have found winning formula, AstraZeneca chief says Covid-19: Oxford-AstraZevria coronavirus vaccine Analysts on Wall Street predict AstraZeneca will release earnings per share of $1.47. Go here to track AstraZeca stock price in real time. AstraZeneca sees revenue and core earnings per share growing by double-digit percentages in 2024, the pharmaceuticals major said as it reported fourth-quarter results.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

How much time have you spent trying to decide whether investing in AstraZeneca? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, share, drug, say, earnings, vaccine, strong, and the most common words in the summary are: astrazeneca, company, news, bloomberg, drug, share, pharmaceutical, . One of the sentences in the summary was: Strong cancer division helped offset a wipeout for sales of Covid treatments. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #company #news #bloomberg #drug #share #pharmaceutical.